All Blogs / Industries / Medical / Pharmaceutical / New

21st Century Cures for Pharmaceutical Marketing

In what Public Citizen described as an "Early Gift for the Pharmaceutical Industry" (see here), the Senate this week passed the 21st Century Cures Act (21st CC), which contains many provisions that will benefit the pharmaceutical industry...Show More Summary

FDA’s Lax Enforcement Trend Continues

FDA continues to issue fewer and fewer warning and untitled letters. As of today (8 December 2016) FDA has issued only 5 enforcement letters (4 untitled and 1 warning letter) compared to 9 letters in 2015. Perhaps in 2017 FDA will issue...Show More Summary

Plan Sponsors Like More Transparent PBMs—Yet Not All Choose Transparency

Pharmacy benefit managers (PBMs) are facing unprecedented criticism about their business practices and levels of transparency. Which got me wondering: What do plan sponsors—the PBMs’ customers—think about their PBMs? For the answer,Show More Summary

Introducing a Special Issue of PLOS Medicine: Clinical Implications of Cancer Genomics

Senior Editor Richard Turner discusses the contents of the Cancer Genomics Special Issue’s first week. This month, PLOS Medicine’s content is devoted entirely to our special issue on the clinical implications of cancer genomics—two leading

Novo Nordisk Sheds New Light on PBM Rebates, the Gross-to-Net Bubble, and Warped Channel Incentives

Novo Nordisk just released new data on the channel economics and pricing for its insulin products. See Perspectives from NNI President Jakob Riis on pricing and affordability Like many manufacturers of relatively undifferentiated products, Novo Nordisk is trapped by a gross-to-net rebate bubble. Show More Summary

CBI’s 8th Hub and SPP Model Optimization

CBI’s 8th Hub and SPP Model OptimizationFebruary 22-23, 2017 | Philadelphia, PADon’t miss the 8th installment of the industry’s must-attend meeting for sharing breakthrough strategies surrounding service model design and enhancementShow More Summary

New Directions for FDA, Part 2 – Regulatory Matters

In Part 1 about change facing FDA, we looked at the 21st Century Cures Act and some of the change that would be in store for FDA. But in this post-election cycle, there is more than pending legislation that could … Continue reading ...

Can This Work for Pharma? The Continual Quest of Creative Advertisers

PM360 magazine is asking its readers find marketing campaigns and tactics used by consumer packaged goods, retail, and other industries to give pharma marketers some fresh ideas. Here's what one ad agency SVP Executive Creative Director...Show More Summary

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post

About 22 weeks ago, Emily Maynard Johnson, who appeared on ABC's The Bachelor and The Bachelorette, posted the following Diclegis promotion to her Instagram account: I assume you've noticed that all the ISI (Important Safety Information)...Show More Summary

CVS Changes Direction With Surprise OptumRx Deal

Well, CVS Health blinked. In July 2017, CVS Health’s retail pharmacies will become a preferred retail channel for 90-day prescriptions dispensed to OptumRx’s commercial clients. Here’s the press release: OptumRx and CVS Pharmacy Partner...Show More Summary

New Directions for FDA, Part 1 – 21st Century Cures

One of the often stated priorities for lame-duck Congress has been voting on the 21st Century Cures Act. In a press release from Saturday, November 26 from the House Energy and Commerce Committee, the House is set to vote on … Continue reading ?

Drug Channels News Roundup, November 2016: CVS Caremark, Generic Drugs, Health-System Pharmacies, and the FDA

Hope everyone enjoyed the Thanksgiving holiday! Now that you’ve stretched your stomach, stretch your mind with some food for thought. In this issue: Dispensing oncology practices win their battle with PBM CVS Caremark 2016 was a record...Show More Summary

Expanded Access Programs 2017

Expanded Access Programs 2017March 9-10, 2017 | Washington, DCThe evolving political landscape is transforming and expanding patient access to experimental and unapproved drugs. CBI’s Expanded Access Programs is dedicated to the nuances and intricacies of designing and implementing early access programs. Show More Summary

CBI’s 12th Life Sciences Trade and Channel Strategies

CBI’s 12th Life Sciences Trade and Channel StrategiesDecember 13-14, 2016 | Philadelphia,’t miss the must-attend event for industry trade, channel, account and pharmacy strategy professionals!CBI’s Annual Trade...Show More Summary

Copyright © 2015 Regator, LLC